top of page

Antibody oligonucleotide conjugates as an RNA strategy with the CEO of Avidity Biosciences

Sarah Boyce explains the rationale for using AOCs against muscle disorders like myotonic dystrophy type 1 and DMD, and describes the clinical data Avidity has collected so far.



Comments


Join the BiotechTV mailing list

Thanks for subscribing!

bottom of page